Results 131 to 140 of about 15,380 (223)

Resultados del tratamiento quirúrgico del cáncer de páncreas [PDF]

, 2017
El tratamiento del cáncer de páncreas requiere un enfoque multidisciplinar, debido tanto al diagnóstico tardío como a la complejidad quirúrgica, que obliga en muchos casos a tratamientos no quirúrgicos.
Grado Alonso, Javier de, Rodin Rodríguez, Mario   +1 more
core  

Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma

Journal of Health Economics and Outcomes Research
Background Further research is needed to determine real-world costs of first-line (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), modified FFX (mFFX), and gemcitabine with nab-paclitaxel (GnP). Objectives To describe healthcare costs by treatment regimen, stratified by commercial and Medicare Advantage ...
Syvart Dennen, Marty Masek, Paul Cockrum, Elizabeth Nagelhout, Ravi Paluri   +4 more
openaire   +2 more sources

Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery

International Journal of Nanomedicine, 2013
Qian Zhan,1 Baiyong Shen,1 Xiaxing Deng,1 Hao Chen,1 Jiabin Jin,1 Xing Zhang,2 Chenghong Peng,1 Hongwei Li1 1Department of General Surgery, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China ...
Zhan Q, Shen B, Deng X, Chen H, Jin J, Zhang X, Peng C, Li H   +7 more
doaj  

Feasibility study of FOLFIRINOX as first-line chemotherapy for metastatic pancreatic cancer (KOBE FOLFIRINOX study)

Annals of Oncology, 2017
Yukimasa Hatachi, Hironaga Satake, Takeshi Kotake, Takatsugu Ogata, Yoshihiro Okita, Hisateru Yasui, Akihito Tsuji   +6 more
openaire   +1 more source

The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. [PDF]

Support Care Cancer
Strijk GJ, van Diepen AE, Wilmink JW, Rietjens JAC, Haberkorn BCM, Stiggelbout AM, Homs MYV, de Vos-Geelen J, van Eijck CHJ, van Eijck CWF.   +9 more
europepmc   +1 more source

Case Report: long complete metabolic response assessed by LAFOV FDG-PET/CT to FOLFIRINOX in first-line treatment of metastatic low-differentiated pancreatic carcinoma. [PDF]

Front Med (Lausanne)
Abgral R, Dzuko Kamga J, Metges JP, Salaun PY.   +3 more
europepmc   +1 more source

<i>NR3C1</i>, <i>LAX1</i>, and <i>RCAN3</i> as Circulating Epigenetic Biomarkers for Prognosis and Chemotherapy Response Prediction in Metastatic Pancreatic Cancer. [PDF]

MedComm (2020)
Cano-Ramírez P, Toledano-Fonseca M, Cano-Osuna MT, Herrera-Casanova N, Carrillo-Pecero E, Rodríguez-Ariza A, Aranda E, García-Ortiz MV.   +7 more
europepmc   +1 more source

Neoadjuvant therapy in resectable and borderline resectable pancreatic cancer-safe but standard of care? [PDF]

Gland Surg
Lee JJ, Desai CS, Kim HJ.
europepmc   +1 more source

Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized controlled trial. [PDF]

BMC Cancer
Jung HS, Choi J, Park SJ, Han Y, Cho YJ, Yoon J, Oh DY, Yoon YS, Kim JW, Lim CS, Park JH, Choi IS, Hong TH, Kim HS, Jeung HC, Ahn KS, Kim JY, Yu YD, Kim JW, Hwang HK, Lee CK, Choi HJ, Jung YK, Park K, Yoon JH, Han IW, Hong JY, Seo HI, Do Yang J, Jeon SY, Yang SJ, Chon HJ, Kwon W, Park JS, Shan YS, Lee MA, Jang JY.   +36 more
europepmc   +1 more source

Therapie des lokal fortgeschrittenen Pankreaskarzinoms mit FOLFIRINOX [PDF]

Der Chirurg, 2016
O. Strobel, M. W. Büchler
openaire   +1 more source